Chalisa Pansin
Acute Care · Las Vegas, NVNPI 1619627213
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Abiomed at 38.7% of the total. Reporting peaked in 2023 at $1,534 and has fallen 50.4% since, to $760 in 2025.
Across 112 payments — averaging $23.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$1K
- Abbott$408
- Novo Nordisk$210
- Dexcom, Inc.$166
- Edwards Lifesciences$160
- Pfizer$149
- plus $537 from 14 others
What the payments were for
- Food & beverage$2,660100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 55 | $1,029 |
| Abbott | 6 | $408 |
| Novo Nordisk | 10 | $210 |
| Dexcom, Inc. | 10 | $166 |
| Edwards Lifesciences | 1 | $160 |
| Pfizer | 2 | $149 |
| AstraZeneca | 7 | $122 |
| Lilly USA, LLC | 4 | $80 |
| Amgen | 4 | $68 |
| AbbVie | 2 | $53 |
| Novartis | 2 | $38 |
| Bayer | 1 | $26 |
| Galderma Laboratories, L.p. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| UCB, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,660 in reported general payments places this provider in the 85th percentile of 129 acute care providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 13 | $13,259 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $416 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $187 |
| Losartan Potassium | 12 | $183 |
| Amlodipine Besylate | 17 | $114 |
| Alprazolam | 12 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $210 | $13,25913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 129 acute care providers in Nevada.
Other acute care in Las Vegas
- Eileen JustoLas Vegas$20K
- Krystal CoffmanLas Vegas$6K
- Ticey HarrisLas Vegas$4K
- Bibi KooLas Vegas$4K
- Helen BallertLas Vegas$3K
- Jenesa Aguiluz-DizonLas Vegas$2K
- Brianna AbneyLas Vegas$2K
- Anita LaksonLas Vegas$2K
- Christine ApelLas Vegas$2K
- Carrie LoftonLas Vegas$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.